Posts Tagged CMO

Growing Turkish Pharma Market Attracts Investment Despite Challenges

by

A growing pharmaceutical market, solid infrastructure and ready access to other emerging markets, such as North Africa and the Middle East, as well as Eastern Europe, make Turkey an attractive location for global pharmaceutical companies. But an emphasis on localization, tough pricing regulations, a depreciating currency and a sluggish drug approval system make the market […]

Learn more

Five Themes That Will Drive the CMO Industry

by

CMO executives are focusing on M&A activity, new business models, and fundraising limits. Trade shows provide a good opportunity to gauge the temperature of the contract development and manufacturing organization (CDMO) industry and find out which trends and concerns are most on people’s minds. Five themes really stood out from conversations at the CPhI Worldwide […]

Learn more

Peptide API Market Growth Expected to Continue

by

CMOs with existing expertise in and capacity for development and manufacture of peptide drugs may find themselves uniquely positioned to take advantage of a surge in interest in such products. As the ability to synthesize these products grows and more dosage forms become available, more companies are adding peptide products—including potential biosimilars as some of […]

Learn more

Innovation vs. Capacity: How CMOs Compete

by

The strategies of a innovation-driven CMO may be different than a capacity-driven CMO. While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract manufacturing organization (CMO) industry can be segmented along obvious lines such as API versus drug product manufacturers, biologics versus […]

Learn more

What’s Next for the CMO Industry?

by

CMOs that offer an innovative service-oriented model will dominate the industry. Contract manufacturing and contract development and manufacturing organizations (CMOs and CDMOs) are an entrenched and critical component of the bio/pharmaceutical industry, but they have proven to be more important to some segments of the industry than others. A bio/pharma company’s relationship with its CMOs […]

Learn more

Supply Chain Diversity Efforts Find Challenge in CMO Sector

by

Most global bio/pharmaceutical companies put a priority on diversity within their supply chains. Websites for many large companies—including Pfizer, Janssen, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca and Merck, for example—include pages dedicated to their supply diversity programs and emphasize the importance of diversity in their contracting activities. However, bio/pharma companies find it challenging to find minority- […]

Learn more

Epirus Bankruptcy Underscores Biosimilar Challenges

by

The recent bankruptcy filing of Epirus Pharmaceuticals, an early stage company developing biosimilars, is a stark reminder of the risks inherent in biosimilar drug development. The company had previously shed 40% of its workforce and ceased late-stage development of its lead asset, a biosimilar version of Johnson & Johnson’s Remicade, but was attempting to maintain […]

Learn more

Vetter to Build US Commercial Facility

by

Vetter Pharma International will build a 1.2 million-square-foot (112,000-square-meter) commercial injectables manufacturing facility in the US. The company has acquired a 17 acre (7 hectare) site in Des Plaines, Ill., near Chicago’s O’Hare Airport and its clinical manufacturing operation in Skokie. Vetter plans to spend $320 million over a 10-year period to build out the […]

Learn more

Global Bio/pharma Continues to Spend on PP&E

by

Global bio/pharma companies continued to invest heavily in new capital assets in 2015. Capital expenditure (capex) by the largest US and European bio/pharma companies experienced robust growth in 2015. Analysis of 21 of the top 25 bio/pharma companies (by revenue) revealed that total spend on property, plant and equipment grew by 12.1% to $21.7 billion […]

Learn more